Quintiles announced the release of Quintiles Infosario, a business-to-business platform that enables customers to leverage data for improved collaboration and decision-making throughout the drug development process.
“Quintiles Infosario is a fully integrated platform that enables significant advances in the drug development process,” said Tom Grundstrom, Quintiles Infosario Global Head. “The technology makes it possible to turn the wealth of data that our company possesses into actionable insights for our customers. Through the platform’s intuitive user interface, key stakeholders will be able to make faster, better-informed decisions about the programs and therapies they are working on.”
Quintiles’ latest reporting and analytics technology integrates, synchronizes, and standardizes subject, operational and management data automatically across a multitude of systems. The platform transforms data and information into meaningful insights to Quintiles’ customers using a secure, web-based front end with a drill path from insight to clinical data. Quintiles Infosario’s reporting and analytics capabilities are among the first features that will be available to select customers beginning later this month.
In addition, customers can fulfill all or parts of their clinical IT system needs through Quintiles Infosario’s cloud-based Systems as a Service. Infosario combines IT provisioning, including configured systems with core clinical business process delivery. By using Systems as a Service, customers will have direct, cost-effective access to IT systems such as safety management and clinical trial management–the same systems that serve Quintiles business.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.